Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Pericardial mesothelioma

Pericardial mesothelioma is a malignant neoplasm of the mesothelial cells of the pericardium. The primary form arises in this serous membrane and must be distinguished both from pericardial involvement by pleural mesothelioma and from the more common metastases of other tumors. Growth is often diffuse along the pericardial layers, with thickening, nodules and infiltration of surrounding structures; a circumscribed mass is one possible presentation, but the initial picture may be dominated solely by effusion or constriction.

Its rarity and resemblance to more common pericardial diseases favor diagnostic delay. Recurrent effusion, progressive constriction or nodular thickening warrants an etiological investigation even when initial cytology is negative. Diagnosis and treatment depend on integrating hemodynamics, imaging, pathology and oncology. Disease-specific therapeutic evidence remains limited, and many systemic strategies are drawn from experience with mesothelioma at other sites.

Etiology, risk factors and biology

The association with asbestos, firmly established for pleural mesothelioma, is less clearly defined for pericardial disease. Available studies are small and yield heterogeneous results; exposure history should be obtained, but its absence must not lower suspicion to the point of excluding the disease. Age and sex distributions also vary across case series, which are subject to selection bias and encompass a broad age range.

Hereditary predisposition to mesothelioma may be relevant when there is an unusual age at onset, multiple personal tumors or a suggestive family history. BAP1 is an important gene in mesothelial biology and predisposition syndromes, but an alteration in the tumor does not automatically imply a germline variant. Genetic counseling considers the overall context and whether constitutional testing is appropriate, avoiding the interpretation of every immunohistochemical result as a hereditary diagnosis.

Neoplastic transformation involves pathways of tumor suppression, cell-cycle control and growth regulation. Alterations in BAP1, CDKN2A and other pathways have also been observed in pericardial tumors, but limited case numbers prevent frequencies or prognostic implications from being defined with the precision available for pleural disease. Molecular testing may clarify difficult cases or guide enrollment in a trial; the presence of a variant does not by itself demonstrate the efficacy of a targeted therapy.

Growth tends to follow the serosal surface and may obstruct lymphatic drainage, invade epicardial fat and reach the myocardium. The thickened tissue progressively forms a poorly distensible sheath that limits filling. Solid and fluid components can both contribute to hemodynamic compromise, explaining why simply draining an effusion sometimes relieves symptoms only partially.

Pathology and classification

Gross findings may include pericardial nodules, confluent plaques or an infiltrating sheath encasing the heart. Effusion may be serous, serosanguineous or frankly hemorrhagic; fluid appearance may provide a clue but remains nonspecific. Adhesions and fibrosis may conceal small neoplastic components, while infiltration of deeper structures determines whether complete resection is feasible.

The main histological patterns are epithelioid, sarcomatoid and biphasic. The epithelioid component may show tubulopapillary or solid architectures; the sarcomatoid component contains spindle cells within variable stroma, while the biphasic form combines both appearances. A limited biopsy may underestimate this heterogeneity. The pathologist must distinguish these findings from metastatic carcinoma, sarcoma and reactive mesothelial proliferation, correlating the sample with its anatomical site.

Demonstration of invasion into underlying tissue is a central element in diagnosing malignancy. Atypia and proliferation can be difficult to interpret in inflamed serous membranes; conversely, some tumors contain relatively bland cells. A biopsy preserving the surface, stroma and interface with deeper tissues provides different information from a superficial fragment or isolated cells dispersed in fluid.

Pathophysiology: effusion, tamponade and constriction

Neoplastic effusion results from altered permeability, inflammation and impaired fluid reabsorption. Its impact depends on the rate of accumulation and pericardial compliance: a relatively small volume may be dangerous if it develops quickly, whereas slow accumulation may reach larger volumes before compromising circulation. Loculated distribution and adhesions may cause selective compression and a less typical presentation than circumferential tamponade.

In cardiac tamponade, pericardial pressure restricts filling, reduces stroke volume and activates compensatory responses such as tachycardia and vasoconstriction. Instability may progress to shock. Findings depend on chamber pressures, volume status and fluid distribution, so the absence of any single clinical or echocardiographic sign is insufficient to rule out significant hemodynamic compromise.

Constriction, in contrast, arises from loss of distensibility of the pericardial sheath, with restricted diastolic filling and increased ventricular interdependence. It can produce marked systemic venous congestion, ascites and edema even with preserved ejection fraction. In effusive-constrictive disease, fluid and persistent restriction coexist: after drainage, improvement in intrapericardial pressure may leave an important hemodynamic component attributable to the infiltrated covering.

Myocardial invasion adds dysfunction and arrhythmias; coronary or great-vessel involvement may cause ischemia or obstruction. Dyspnea therefore results from varying combinations of low output, congestion, associated pleural effusion and damage to adjacent structures. Assessing effusion solely by its volume risks overlooking the solid component of the disease.

Clinical manifestations, history and physical examination

Onset may involve progressive dyspnea, chest discomfort, fatigue or reduced exercise capacity. With constriction, edema, abdominal distension, early satiety and weight gain from fluid retention predominate; fever and weight loss may reflect the neoplastic process. Pericarditic-type pain is possible but not obligatory. Some patients first present with tamponade.

The pericardial history reconstructs previous drainage procedures, the speed of recurrence, cytology findings, response to treatment and the development of signs of constriction. Occupational exposures, other neoplasms, thoracic irradiation, infections and systemic diseases are documented. Persistence despite initially plausible therapy should prompt reassessment of the etiology, especially with nodularity or progressive thickening.

On physical examination, clinicians look for jugular venous distension, edema, ascites, hepatomegaly, tachycardia and signs of hypoperfusion. Pulsus paradoxus and hypotension may support suspicion of tamponade; Kussmaul's sign may occur with constriction. These findings describe physiology and require integrated confirmation by echocardiography. Attention to perfusion, breathing and urine output takes priority when deterioration is rapid.

Diagnostic imaging and investigations

Echocardiography assesses fluid distribution, chamber collapse when present, respiratory variations in flows and inferior vena cava characteristics. Doppler and tissue Doppler studies help identify constrictive physiology through evaluation of septal motion and ventricular interdependence. Superficial masses and thickening may be poorly visualized: an echocardiogram documenting only effusion does not complete the investigation of its cause.

Contrast-enhanced chest CT depicts nodularity, thickening, adhesions, mediastinal spread and relationships to the pleura, great vessels and lungs. This study is also important for establishing whether disease is centered in the pericardium or represents extension of a pleural tumor. Absence of a single discrete mass is not reassuring when the covering shows diffuse infiltrative progression.

Cardiac magnetic resonance imaging integrates anatomy, tissue characterization and function: it characterizes the pericardium, assesses enhancement and myocardial involvement, and helps describe filling mechanisms. Both inflammation and neoplasia may cause enhancement, so findings must be interpreted alongside morphology, distribution and evolution. Deep extension and the constrictive component may be important even when measured thickness is modest.

FDG PET/CT may help select an area for sampling and assess extracardiac distribution or treatment response. Pericardial uptake is not specific for malignancy and may increase with inflammation or recent procedures. Blood tests quantify systemic consequences and organ reserve; tumor markers in blood or fluid alone lack sufficient accuracy to confirm or rule out this tumor.

Cytological, histological and molecular diagnosis

Pericardiocentesis, when necessary because of hemodynamics or symptoms, provides material for cytology and a cell block. Suspected mesothelioma must be communicated to the laboratory because reactive mesothelial cells may exhibit atypia and neoplastic cells may be sparse. Negative or equivocal cytology leaves the diagnostic question open, especially in forms infiltrating the wall without shedding many cells into the cavity.

A targeted pericardial biopsy of nodules or suspicious areas is often needed to document architecture and invasion. A surgical, thoracoscopic or other approach is chosen according to anatomy, stability and procedures already indicated. Random sampling of a fibrotic area may be unrepresentative; image-guided planning increases the likelihood of obtaining useful tissue. A benign result inconsistent with infiltrative progression requires multidisciplinary reassessment of both the specimen and sampling target.

The immunohistochemical panel must establish mesothelial lineage and assess alternatives. Calretinin, WT1, D2-40 and relevant cytokeratins can support mesothelial origin; epithelial markers such as claudin-4 and MOC-31 aid comparison with metastatic carcinomas. Multiple concordant markers are used, tailored to morphology and clinical suspicion. Expression may be less complete in sarcomatoid components, making correlation with tissue findings and extent even more important.

Nuclear loss of BAP1, loss of MTAP and homozygous deletion of CDKN2A by FISH may support malignancy in a proliferation already identified as mesothelial. Retention of these markers does not rule out mesothelioma. Internal controls, technical quality and morphological context are essential; BAP1 loss may also occur in other neoplasms and is not a universal marker of mesothelial origin. Test performance is less well defined in the pericardium than at better-studied sites.

The differential diagnosis includes carcinoma metastases, lymphoma, other pericardial tumors, infectious or autoimmune pericarditis and fibrosing processes. Distinguishing a primary lesion from pleural mesothelioma with contiguous extension requires clinical-radiological mapping of the entire disease. The diagnostic conclusion should specify histological type, sample adequacy and limitations, and the findings supporting malignancy, rather than allowing a single marker to replace integrated judgment.

Determining extent and operability

Staging assesses the myocardium, coronary grooves, great vessels, diaphragm, pleura, lymph nodes and possible distant sites. CT, MRI and PET are used according to the clinical question. A TNM system developed for pleural mesothelioma does not automatically provide a valid description of primary pericardial disease; accurate anatomical characterization is therefore essential for treatment discussions.

Resectability depends on whether the tumor can be removed at an acceptable functional cost. A limited lesion offers different prospects from a diffuse sheath invading myocardium and coronary arteries. Nutritional status, hepatic congestion, and renal and respiratory function influence risks from procedures and systemic therapy. An operation intended to control the neoplasm must also be distinguished from one primarily intended to improve filling and relieve symptoms.

Effusion management and surgery

In unstable tamponade, drainage takes priority. A percutaneous or surgical approach is chosen based on accessibility, fluid distribution and available expertise. Pressure, function and the course of the effusion are monitored during and after the procedure. Hemodynamic relief often allows completion of the diagnosis and initiation of care, but persistent constriction may limit recovery.

For recurrent effusion, prolonged drainage or a pericardial window may be considered, taking diagnostic needs, procedural risks and oncological treatment into account. These procedures mainly address fluid accumulation. Any use of intrapericardial treatments requires specialist assessment, because data from metastatic effusions associated with other cancers do not establish disease-specific efficacy in pericardial mesothelioma.

Pericardiectomy or other resections may relieve constriction or remove localized disease in selected patients. Diffuse invasion frequently makes complete radical resection impossible and increases the risk of coronary or myocardial injury. Symptom benefit, achievable margins and postoperative recovery must be considered together. Simply increasing the extent of resection does not guarantee a demonstrated survival benefit for this rare neoplasm.

Systemic therapy, radiotherapy and supportive care

The combination of pemetrexed and a platinum agent is among the systemic approaches used in published experience, largely extrapolated from pleural mesothelioma. Cisplatin or carboplatin is considered according to renal function, general condition and treatment goals. Observed associations between chemotherapy and survival in pericardial case series are vulnerable to selection bias and do not amount to randomized evidence of efficacy. Treatment expectations must therefore be proportionate to the available evidence.

Tolerability requires attention to bone marrow reserve, renal function, nutritional status and congestion. When pemetrexed is used, vitamin supplementation and supportive measures follow the relevant protocol. Hydration required for some platinum regimens must be adapted to hemodynamics, especially with constriction or heart failure. Systemic toxicity can destabilize the heart even without direct drug-induced myocardial damage.

Immunotherapy, including checkpoint inhibitors studied in pleural mesothelioma, is considered in selected or investigational settings. Experience with primary pericardial mesothelioma remains limited and does not justify automatically transferring benefits, sequences or criteria from pleural disease. Discussions include histology, prior therapies, access to treatment and risk of immune-mediated events, particularly relevant when the myocardium and pericardium are already compromised.

Targeted therapies or other molecular profile-guided strategies may be assessed when a specific alteration has relevant supporting evidence or a research protocol exists. BAP1 and other diagnostic abnormalities do not identify a universally effective standard treatment. Participation in registries and studies for rare tumors may support better-informed decisions, while keeping a biological hypothesis distinct from demonstrated clinical benefit.

Radiotherapy may have a role in local control or palliation of selected sites. Encapsulation of the heart, its motion and proximity to the lungs and esophagus limit the ability to deliver effective doses without significant harm. Planning must define a realistic aim and consider the overall treatment burden; prospective data are insufficient to recommend a uniform pericardial radiotherapy regimen.

Supportive care includes management of congestion, relief of pain and dyspnea, nutritional support and integrated palliative care. In preload-dependent states, excessive reduction in circulating volume may worsen cardiac output, so diuretics are titrated to the actual physiology. Persistent symptoms require distinguishing fluid, constriction, infiltration and extracardiac disease, since each mechanism offers different intervention options.

Prognosis and follow-up

Prognosis is generally unfavorable, particularly because of advanced diagnosis, local spread and the difficulty of radical resection. Published courses are heterogeneous and include longer survival in selected patients. Small case series, treatment differences and preferential publication of unusual cases limit the meaning of median estimates. Histological type, distribution, functional reserve and response must be considered together for individual prognostication.

Follow-up combines clinical and echocardiographic assessments with CT or MRI according to the sites involved. Response assessment encompasses fluid volume, nodularity, solid component, function and constrictive signs, as well as extracardiac disease burden. PET may address selected questions, accounting for inflammatory causes of uptake. Increasing dyspnea, recurrent edema, hypotension or new rhythm disturbances warrant reassessment ahead of scheduled visits.

Complications

The main complications are recurrent tamponade, constriction, heart failure, low cardiac output, arrhythmias and ischemia due to involvement of adjacent structures. Prolonged congestion can impair liver and kidney function, further reducing tolerance of treatment. Pleural, mediastinal or distant spread contributes to respiratory and systemic injury.

Procedural complications include bleeding, injury to cardiac structures, infection and hemodynamic deterioration after drainage or surgery. Antineoplastic therapies add specific toxicities that must be distinguished from progression and persistent constrictive physiology. Coordinated management permits intervention on modifiable components and adjustment of treatment intensity according to benefit, symptom burden and patient preferences.

References
  1. Ji Q et al. Expert Consensus on the Diagnosis and Treatment of Malignant Pericardial Mesothelioma. Med Research. 2025;1(1):122-130.
  2. Chapel DB et al. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Translational Lung Cancer Research. 2020;9(Suppl 1):S3-S27.
  3. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  4. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  5. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  6. Mousavi N et al. Assessment of Cardiac Masses by Cardiac Magnetic Resonance Imaging: Histological Correlation and Clinical Outcomes. Journal of the American Heart Association. 2019;8(1):e007829.
  7. Shenoy C et al. Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study. European Heart Journal. 2022;43(1):71-80.
  8. Mori S et al. Pericardial effusion in oncological patients: current knowledge and principles of management. Cardio-Oncology. 2024;10:8.
  9. Takeda K et al. Higher sensitivity of pericardial fluid cytology than biopsy in malignant effusions with potential explanation of false-negative cytology: A multi-institutional analysis. Cytopathology. 2025;36(1):31-40.
  10. Lestuzzi C. Neoplastic pericardial disease: Old and current strategies for diagnosis and management. World Journal of Cardiology. 2010;2(9):270-279.
  11. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.